Transcript Schistosomiasis & Sth Control & Elimination LF Oncho

Schistosomiasis and STH
control and elimination ICOSA
(LF, Oncho and trachoma)
Professor Alan Fenwick OBE
SCI
Imperial College
London
The pharmaceutical industry has increased its contribution
to global health
Merck & Co Inc – have reconfirmed their
commitment to donate Mectizan for as long
as needed for both onchocerciasis and
filariasis in Africa – since 1986
Johnson & Johnson – from 2012 donated
200 million tablets mebendazole per year
for intestinal worms
GlaxoSmithKline – have already donated over 4
billion tablets of albendazole for lymphatic
filariasis and will continue until elimination is
achieved (600 million in 2014)
In 2010 GSK committed an additional 400
million tablets a year to deworm school aged
children in Africa
The pharmaceutical industry has increased its contribution
to global health
Pfizer – originally committed to provide azithromycin
for trachoma in 1999
In 2014 they reached 60 million
In 2015 115 million doses will be shipped
Novartis is continuing their commitment to MDT for
leprosy
EISAI
In October 2010, EISAI committed to provide 2
billion tablets of DEC for LF which is used with
albendazole outside of Africa
In 2006 Merck KGaA committed to 20 million
praziquantel tablets/year. From 2012 they
increased their commitment annually to reach 250
million tabs/yr by 2016
Enough to treat 100 million children per year
Funding for delivery of these drugs
• DFID - £50 million in 2008 – increased to £245 million in 2012
• USAID $100 million in 2006 – increased to $450 million in 2010
• The ENDFUND – has a fund raising target of $100 million
• The World Bank – supports Yemen
• Private donors support selected programmes
• Bill and Melinda Gates Foundation
SCI supported countries 2014/15
Total treatments to date over 100 million
Yemen
Mauritania
Mali
Niger
Sudan
Senegal
Burkina Faso
Ethiopia
Liberia
Uganda
Ghana
Cote D’Ivoire
DRC
Tanzania
Burundi and Rwanda
Malawi
DFID supported (over 29
million reported to date)
Private Investor supported
Zambia
Madagascar
Targeted yet to be supported
DFID and Private investor
Mozambique
Legacy country (now USAID
supported)
Zimbabwe
New countries (2014/15)
Ethiopia DRC Madagascar Sudan
The mapping of schistosomiasis and STH in Ethiopia is complete
We estimate that 10 million people children need annual treatment for
schistosomiasis
Over 30 million children need treatment for STH – every year or even tice a year.
Mapping of schistosomiasis in DRC is ongoing
The first treatment in December 2014 targeted 1 million children
Mapping of schistosomiasis in Madagascar is ongoing (finish by July 2015)
The first treatment in December 2014 targeted 350,000 children and we will scale up
to 1.5 million during 2015
Sudan – treating 4.3 million children this month
CNTD Liverpool
CNTD as partner with SCI in ICOSA
The ICOSA countries of Liberia, Mozambique, and Zambia are managed
by CNTD
Liberia work has been on hold due to Ebola
Mozambique pzq and albendazole treatment has continued
– 3.1 million treated in 2014 - 7.7 million planned for 2015
Mapping has been carried out in Zambia
SCI treatment plans – existing funding
and our expansion wish list
2 million extra treatments for every £1 million we can
raise
60
50
40
30
20
10
0
2014
2015
2016
2017
current plans with exisiting funding
2018
2019
Likely future praziquantel availability
Millions of
tablets
2013
2014
2015
2016
USAID
70
70
60
20
DFID
40
40
70
70
Other
20
40
20
20
Merck
25
75
105
250
Total
155
225
255
360
To treat
60m
90m
100m
140m
Where we are now
Where we can get with
existing tools and strategies
Where we can get with
new tools and strategies
Diseases Targeted For Control/Elimination
Schistosomiasis
Soil-Transmitted
Helminthes
And the new tools are Safe Water and Hygiene
2020
Goals
CNTD Liverpool
Shrinking the LF map - Ethiopia and DRC
The mapping of LF in Ethiopia is complete
112 districts across the country were endemic for the disease
12 million people are exposed to infection. But the CNTD survey result
was 60% lower than the current WHO estimate of 30 million.
Mapping of LF in DRC is more than 95% complete
The number of people at risk seems significantly lower than the 49
million estimated by WHO.
According to the reports of 17 African countries, 113,555,882 were
treated for LF in 2013 – with albendazole and mectizan or DEC
CNTD Liverpool
Review of the LF endemicity status in Gambia
Results of LF TAS surveys in the Gambia was reviewed last week by the AFRO
Regional Programme Review Group (RPRG) and concluded that MDA for LF will
not be required for the Gambia.
Gambia is now in line to be removed from the list LF endemic countries.
Capacity building for laboratory activities in Sierra Leone aided the diagnostics
efforts for Ebola in the country. Technicians trained in Accra Ghana
participated in the Ebola laboratory activities.
Professor Moses Bockarie was actively involved in discussion about the new
entity that will replace APOC in 2016. He is a member of the Committee of
Sponsoring Agencies (CSA). Transition Task Force (TTF) and the Regional
Programme Review Group (RPRG) for NTDs.
APOC
The African Programme for Onchocerciasis Control is due to close down
and a new programme PENDA Programme for the Elimination
of Neglected Diseases in Africa will replace it
Onchocerciasis is heading for elimination – blindness has almost
disappeared – but how long will this take to reach elimination?
According to the reports of 24 countries 100,693,541 persons were
treated for onchocerciasis with Mectizan in 2013
Guinea Worm (WHO data)
• January–October 2014
• 115 cases compared with 139 cases for the same months in 2013, a decrease of
17%
• Total number of cases in 2013 148 reported cases , compared with 542 in 2012,
a decrease of 73%
• Endemic countries in 2014
• 4 endemic countries (Chad, Ethiopia, Mali and South Sudan) compared with 20 in
1990
Zithromax donations
UK Coalition partner activities
SIGHTSAVERS:
Global number of NTD treatments.
In 2013 Sightsavers distributed over 103 million treatments for NTDs targeting Oncho, Trachoma, LF, Schisto and STH
•Trachoma treatments - 9 million.
•Oncho treatments have increased to 34.3 million.
•LF treatments have increased to 44.2 million .
•STH In 2013 Sightsavers distributed 12.5 million treatments
•Schisto In 2013 Sightsavers distributed 3.4 million in 2013.
MALARIA CONSORTIUM
Malaria Consortium is exploring innovative approaches to ensure community engagement in NTD control in
Mozambique
•
Russell Stothard (Director) (CNTD Liverool)
Rachael Thomson, Sally Theobald and Mark Taylor
Programme of implementation research to inform the effective and sustainable
scaling-up of integrated Neglected Tropical Disease (NTD) control initiatives
Rationale for research themes and approaches
Our IR themes and approaches take forward the current needs and priorities of our
embedded country partners, and also reflect calls for action at the international level.
Nana Biritwum – NTDs (LF)
Margaret Gyapong – Social sciences
Louis Tchuem-Tchuente – NTDs (SCH/STH)
Sam Wanji - LF and ONCH
Karsor Kollie – NTDs
scale-up in Nigeria
What are the expected results?
Our results are framed in four outputs:
1: Form a vibrant multidisciplinary IR consortium engaged with national NTD
programmes and international stakeholders
2: Provide rigorous and generalizable evidence to improve and support scale-up of
integrated MDA programmes
3: Develop knowledge management strategy and multi-sectoral platforms for
cross-talk and dialogue, ensuring open access knowledge products
4: Increase research capacity and integrate multi-sectoral evidence for
optimisation of NTD control programmes
Please visit
www.schisto.org
Alan Fenwick
[email protected]
Thank you